ANTHRACYCLINES ROLE IN ADJUVANT TREATMENT OF BREAST CANCER

ANTHRACYCLINES ROLE IN ADJUVANT TREATMENT OF BREAST CANCER

€10.00
Tax included
Quantity
Add to wishlist
In Stock

Anthracyclines are used in the adjuvant treatment of breast cancer for about 25 years. Recently in the light of new data on taxanes and targeted therapies (trastuzumab) that have proven their effectiveness and the emergence of new predictors of sensitivity to anthracyclines, it was asked the following questions:
1. Is it possible to dispense with anthracyclines and taxanes for the benefit of targeted therapies?!
2. Should we prescribe to all patients anthracyclines?!
3. Is there any predictive factors for selecting patients who will benefit most from anthracyclines.
SKU-1109
30 Items
2050-01-01
New

16 other products in the same category:

This website uses cookies to ensure you get the best experience on our website